On May 5, Borui Pharmaceutical announced that its wholly-owned subsidiary, Borui Pharmaceutical Co., Ltd., has successfully achieved the expected goals in the Phase III clinical trial for the weight loss indication of its independently developed BGM0504 injection. According to Jin10, BGM0504 is a dual agonist of GLP-1 and GIP receptors, which can activate downstream pathways of GIP and GLP-1, resulting in biological effects such as blood sugar control, weight loss, and treatment of non-alcoholic steatohepatitis, demonstrating potential for treating various metabolic diseases. Additionally, the BGM0504 injection is currently in Phase III clinical trials for the type 2 diabetes indication in China.
